Endometrial cancer

The Lancet

Volumn 387, Issue 10023, 2016, Pages 1094-1108

  Morice, Philippe ^a,b,c   Leary, Alexandra ^a   Creutzberg, Carien ^d   Abu Rustum, Nadeem ^e   Darai, Emile ^f,g,h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f HÔPITAL TENON   (France)

^g CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^h SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONFERENCE PAPER; ENDOMETRIUM CANCER; FEMALE; GENETIC COUNSELING; HISTOLOGY; HUMAN; LYMPH NODE DISSECTION; META ANALYSIS (TOPIC); METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; TUMOR BIOPSY; ADULT; AGED; EARLY CANCER DIAGNOSIS; ENDOMETRIAL NEOPLASMS; GENETICS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MUTATION; NEOADJUVANT THERAPY; PATHOLOGY; PREOPERATIVE CARE; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR INVASION; TUMOR RECURRENCE; UTERINE HEMORRHAGE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; EARLY DETECTION OF CANCER; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC COUNSELING; HUMANS; LYMPH NODE EXCISION; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREOPERATIVE CARE; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; UTERINE HEMORRHAGE;

EID: 84961214057     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00130-0     Document Type: Conference Paper

References (158)

1. J Ferlay, I Soerjomataram, R Dikshit et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 2015 E359 E386
2. D Querleu, F Planchamp, F Narducci the Institut National du Cancer the Societe Francaise d'Oncologie Gynecologique Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Société Française d'Oncologie Gynécologique Int J Gynecol Cancer 21 2011 945 950
3. WM Burke, J Orr, M Leitao the SGO Clinical Practice Endometrial Cancer Working Group the Society of Gynecologic Oncology Clinical Practice Committee Endometrial cancer: a review and current management strategies: part I Gynecol Oncol 134 2014 385 392
4. WM Burke, J Orr, M Leitao the SGO Clinical Practice Endometrial Cancer Working Group the Society of Gynecologic Oncology Clinical Practice Committee Endometrial cancer: a review and current management strategies: part II Gynecol Oncol 134 2014 393 402
5. RL Siegel, KD Miller, A Jemal Cancer statistics, 2015 CA Cancer J Clin 65 2015 5 29
6. ER Evans-Metcalf, SE Brooks, FR Reale, SP Baker Profile of women 45 years of age and younger with endometrial cancer Obstet Gynecol 91 1998 349 354
7. TS Lee, JY Jung, JW Kim et al. Feasibility of ovarian preservation in patients with early stage endometrial carcinoma Gynecol Oncol 104 2007 52 57
8. LR Duska, A Garrett, BR Rueda, J Haas, Y Chang, AF Fuller Endometrial cancer in women 40 years old or younger Gynecol Oncol 83 2001 388 393
9. JV Lacey Jr, VM Chia, BB Rush et al. Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan Int J Cancer 131 2012 1921 1929
10. MA Sheikh, AD Althouse, KE Freese et al. USA endometrial cancer projections to 2030: should we be concerned? Future Oncol 10 2014 2561 2568
11. B Trabert, N Wentzensen, AS Felix, HP Yang, ME Sherman, LA Brinton Metabolic syndrome and risk of endometrial cancer in the United States: a study in the SEER-medicare linked database Cancer Epidemiol Biomarkers Prev 24 2015 261 267
12. TJ Key, MC Pike The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk Br J Cancer 57 1988 205 212
13. MC Pike, RK Peters, W Cozen et al. Estrogen-progestin replacement therapy and endometrial cancer J Natl Cancer Inst 89 1997 1110 1116
14. R Kaaks, A Lukanova, MS Kurzer Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review Cancer Epidemiol Biomarkers Prev 11 2002 1531 1543
15. AG Renehan, M Tyson, M Egger, RF Heller, M Zwahlen Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies Lancet 371 2008 569 578
16. D Grady, T Gebretsadik, K Kerlikowske, V Ernster, D Petitti Hormone replacement therapy and endometrial cancer risk: a meta-analysis Obstet Gynecol 85 1995 304 313
17. DM Purdie, AC Green Epidemiology of endometrial cancer Best Pract Res Clin Obstet Gynaecol 15 2001 341 354
18. E Friberg, N Orsini, CS Mantzoros, A Wolk Diabetes mellitus and risk of endometrial cancer: a meta-analysis Diabetologia 50 2007 1365 1374
19. P Terry, JA Baron, E Weiderpass, J Yuen, P Lichtenstein, O Nyrén Lifestyle and endometrial cancer risk: a cohort study from the Swedish Twin Registry Int J Cancer 82 1999 38 42
20. KE Anderson, E Anderson, PJ Mink et al. Diabetes and endometrial cancer in the Iowa women's health study Cancer Epidemiol Biomarkers Prev 10 2001 611 616
21. J Luo, S Beresford, C Chen et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer Br J Cancer 111 2014 1432 1439
22. T Soini, R Hurskainen, S Grénman, J Mäenpää, J Paavonen, E Pukkala Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland Obstet Gynecol 124 2014 292 299
23. JV Bokhman Two pathogenetic types of endometrial carcinoma Gynecol Oncol 15 1983 10 17
24. LA Brinton, AS Felix, DS McMeekin et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial Gynecol Oncol 129 2013 277 284
25. GF Zannoni, VG Vellone, V Arena et al. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study Virchows Arch 457 2010 27 34
26. C Kandoth, N Schultz, AD Cherniack the Cancer Genome Atlas Research Network Integrated genomic characterization of endometrial carcinoma Nature 497 2013 67 73
27. SA Byron, PM Pollock FGFR2 as a molecular target in endometrial cancer Future Oncol 5 2009 27 32
28. E Kuhn, A Ayhan, A Bahadirli-Talbott, C Zhao, IM Shih Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma Am J Surg Pathol 38 2014 660 665
29. ZM Zhang, S Xiao, GY Sun et al. The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma Int J Gynecol Cancer 24 2014 534 540
30. O Fadare, K Gwin, MM Desouki et al. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium Mod Pathol 26 2013 1101 1110
31. LN Hoang, G Han, M McConechy et al. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma - diagnostic utility of HNF-1β and oestrogen receptor Histopathology 64 2014 585 596
32. YR Hussein, B Weigelt, DA Levine et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations Mod Pathol 28 2015 505 514
33. I Modica, RA Soslow, D Black, C Tornos, N Kauff, J Shia Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma Am J Surg Pathol 31 2007 744 751
34. WG McCluggage My approach to the interpretation of endometrial biopsies and curettings J Clin Pathol 59 2006 801 812
35. FP Dijkhuizen, BW Mol, HA Brölmann, AP Heintz The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis Cancer 89 2000 1765 1772
36. CL Trimble, J Kauderer, R Zaino et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study Cancer 106 2006 812 819
37. C Touboul, B Piel, M Koskas et al. Factors predictive of endometrial carcinoma in patients with atypical endometrial hyperplasia on preoperative histology Anticancer Res 34 2014 5671 5676
38. DO Lee, MH Jung, HY Kim Prospective comparison of biopsy results from curettage and hysteroscopy in postmenopausal uterine bleeding J Obstet Gynaecol Res 37 2011 1423 1426
39. YN Chang, Y Zhang, YJ Wang, LP Wang, H Duan Effect of hysteroscopy on the peritoneal dissemination of endometrial cancer cells: a meta-analysis Fertil Steril 96 2011 957 961
40. A Timmermans, BC Opmeer, KS Khan et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis Obstet Gynecol 116 2010 160 167
41. L Savelli, M Ceccarini, M Ludovisi et al. Preoperative local staging of endometrial cancer: transvaginal sonography vs magnetic resonance imaging Ultrasound Obstet Gynecol 31 2008 560 566
42. O Akbayir, A Corbacioglu, C Numanoglu et al. Preoperative assessment of myometrial and cervical invasion in endometrial carcinoma by transvaginal ultrasound Gynecol Oncol 122 2011 600 603
43. S Jantarasaengaram, N Praditphol, T Tansathit, C Vipupinyo, K Vairojanavong Three-dimensional ultrasound with volume contrast imaging for preoperative assessment of myometrial invasion and cervical involvement in women with endometrial cancer Ultrasound Obstet Gynecol 43 2014 569 574
44. A Andreano, G Rechichi, P Rebora, S Sironi, MG Valsecchi, S Galimberti MR diffusion imaging for preoperative staging of myometrial invasion in patients with endometrial cancer: a systematic review and meta-analysis Eur Radiol 24 2014 1327 1338
45. G Lin, KK Ng, CJ Chang et al. Myometrial invasion in endometrial cancer: diagnostic accuracy of diffusion-weighted 3·0-T MR imaging - initial experience Radiology 250 2009 784 792
46. M Hori, T Kim, H Onishi et al. Endometrial cancer: preoperative staging using three-dimensional T2-weighted turbo spin-echo and diffusion-weighted MR imaging at 3·0 T: a prospective comparative study Eur Radiol 23 2013 2296 2305
47. TJ Selman, CH Mann, J Zamora, KS Khan A systematic review of tests for lymph node status in primary endometrial cancer BMC Womens Health 8 2008 8
48. 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma Gynecol Oncol 125 2012 566 571
49. CH Lai, G Lin, TC Yen, FY Liu Molecular imaging in the management of gynecologic malignancies Gynecol Oncol 135 2014 156 162
50. S Chicklore, G Gnanasegaran, S Vijayanathan, I Fogelman Potential role of multislice SPECT/CT in impingement syndrome and soft-tissue pathology of the ankle and foot Nucl Med Commun 34 2013 130 139
51. S Pecorelli Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium Int J Gynaecol Obstet 105 2009 103 104
52. Union internationale contre le cancer (UICC) TNM: Classification des tumeurs malignes 7th edn. 2009 Wiley-Blackwell New York, NY
53. JN Barlin, Q Zhou, CM St Clair et al. Classification and regression tree (CART) analysis of endometrial carcinoma: seeing the forest for the trees Gynecol Oncol 130 2013 452 456
54. R Murali, RA Soslow, B Weigelt Classification of endometrial carcinoma: more than two types Lancet Oncol 15 2014 e268 e278
55. CL Creutzberg, WL van Putten, PC Koper et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage 1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma Lancet 355 2000 1404 1411
56. HM Keys, JA Roberts, VL Brunetto the Gynecologic Oncology Group A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study Gynecol Oncol 92 2004 744 751
57. Y Todo, H Kato, M Kaneuchi, H Watari, M Takeda, N Sakuragi Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis Lancet 375 2010 1165 1172
58. S Bendifallah, G Canlorbe, E Raimond et al. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion Br J Cancer 110 2014 2640 2646
59. HM Werner, J Trovik, MK Halle et al. Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer PLoS One 9 2014 e90141
60. AG Zeimet, D Reimer, M Huszar et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation J Natl Cancer Inst 105 2013 1142 1150
61. T Bosse, RA Nout, E Stelloo et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results Eur J Cancer 50 2014 2602 2610
62. E Weiderpass, J Antoine, FI Bray, JK Oh, M Arbyn Trends in corpus uteri cancer mortality in member states of the European Union Eur J Cancer 50 2014 1675 1684
63. WT Creasman, F Odicino, P Maisonneuve et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer Int J Gynaecol Obstet 95 suppl 1 2006 S105 S143
64. NR Abu-Rustum, Q Zhou, JD Gomez et al. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care Gynecol Oncol 116 2010 399 403
65. MM AlHilli, KC Podratz, SC Dowdy et al. Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer Gynecol Oncol 131 2013 103 108
66. MM AlHilli, A Mariani, JN Bakkum-Gamez et al. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer Gynecol Oncol 133 2014 485 493
67. S Bendifallah, G Canlorbe, E Raimond et al. An external validation study of nomograms designed to predict isolated loco-regional and distant endometrial cancer recurrences: how applicable are they? Br J Cancer 109 2013 1498 1503
68. M Koskas, M Fournier, D Luton, E Darai, R Rouzier Survival impact of lymphadenectomy stratified by nodal metastatic probability in endometrial cancer Ann Surg Oncol 21 2014 2376 2382
69. S Bendifallah, G Canlorbe, E Raimond et al. External validation of nomograms designed to predict lymphatic dissemination in patients with early-stage endometrioid endometrial cancer: a multicenter study Am J Obstet Gynecol 212 2015 e1 e7
70. CL Creutzberg, RG van Stiphout, RA Nout et al. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials Int J Radiat Oncol Biol Phys 91 2015 530 539
71. A Rodolakis, I Biliatis, P Morice et al. ESGO Task Force for Fertility Preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients Int J Gynecol Cancer 25 2015 1258 1265
72. M Janda, V Gebski, A Brand et al. Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial Lancet Oncol 11 2010 772 780
73. Q Lu, H Liu, C Liu et al. Comparison of laparoscopy and laparotomy for management of endometrial carcinoma: a prospective randomized study with 11-year experience J Cancer Res Clin Oncol 139 2013 1853 1859
74. A Mariani, SC Dowdy, WA Cliby et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging Gynecol Oncol 109 2008 11 18
75. VL Beesley, IJ Rowlands, SC Hayes the Australian National Endometrial Cancer Study Group Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer Gynecol Oncol 136 2015 87 93
76. LC Kilgore, EE Partridge, RD Alvarez et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling Gynecol Oncol 56 1995 29 33
77. H Kitchener, AM Swart, Q Qian, C Amos, MK Parmar the ASTEC study group Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study Lancet 373 2009 125 136
78. P Benedetti Panici, S Basile, F Maneschi et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial J Natl Cancer Inst 100 2008 1707 1716
79. DM Boruta 2nd, PA Gehrig, AN Fader, AB Olawaiye Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review Gynecol Oncol 115 2009 142 153
80. A Mendivil, KM Schuler, PA Gehrig Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes Cancer Contr 16 2009 46 52
81. AB Olawaiye, DM Boruta 2nd Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review Gynecol Oncol 113 2009 277 283
82. VW Setiawan, HP Yang, MC Pike the Australian National Endometrial Cancer Study Group Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 31 2013 2607 2618
83. GH Eltabbakh, J Shamonki, SL Mount Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors Gynecol Oncol 99 2005 309 312
84. M Frumovitz, DK Singh, L Meyer et al. Predictors of final histology in patients with endometrial cancer Gynecol Oncol 95 2004 463 468
85. M Ballester, M Koskas, C Coutant et al. Does the use of the 2009 FIGO classification of endometrial cancer impact on indications of the sentinel node biopsy? BMC Cancer 10 2010 465 471
86. M Ballester, I Naoura, E Chéreau et al. Sentinel node biopsy upstages patients with presumed low- and intermediate-risk endometrial cancer: results of a multicenter study Ann Surg Oncol 20 2013 407 412
87. ID Mavromatis, CN Antonopoulos, IL Matsoukis et al. Validity of intraoperative gross examination of myometrial invasion in patients with endometrial cancer: a meta-analysis Acta Obstet Gynecol Scand 91 2012 779 793
88. F Khoury-Collado, GE Glaser, O Zivanovic et al. Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed? Gynecol Oncol 115 2009 453 455
89. F Khoury-Collado, MP Murray, ML Hensley et al. Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes Gynecol Oncol 122 2011 251 254
90. M Frimer, F Khoury-Collado, MP Murray, RR Barakat, NR Abu-Rustum Micrometastasis of endometrial cancer to sentinel lymph nodes: is it an artifact of uterine manipulation? Gynecol Oncol 119 2010 496 499
91. MM Leitao Jr, F Khoury-Collado, G Gardner et al. Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer Gynecol Oncol 129 2013 38 41
92. CH Kim, RA Soslow, KJ Park et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging Int J Gynecol Cancer 23 2013 964 970
93. JN Barlin, F Khoury-Collado, CH Kim et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes Gynecol Oncol 125 2012 531 535
94. F Vidal, P Leguevaque, S Motton et al. Evaluation of the sentinel lymph node algorithm with blue dye labeling for early-stage endometrial cancer in a multicentric setting Int J Gynecol Cancer 23 2013 1237 1243
95. NR Abu-Rustum The increasing credibility of sentinel lymph node mapping in endometrial cancer Ann Surg Oncol 20 2013 353 354
96. NR Abu-Rustum, F Khoury-Collado, N Pandit-Taskar et al. Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? Gynecol Oncol 113 2009 163 169
97. M Ballester, G Dubernard, F Lécuru et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO) Lancet Oncol 12 2011 469 476
98. J Aalders, V Abeler, P Kolstad, M Onsrud Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients Obstet Gynecol 56 1980 419 427
99. M Onsrud, M Cvancarova, TP Hellebust, CG Tropé, GB Kristensen, K Lindemann Long-term outcomes after pelvic radiation for early-stage endometrial cancer J Clin Oncol 31 2013 3951 3956
100. CL Creutzberg, RA Nout, ML Lybeert the PORTEC Study Group Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma Int J Radiat Oncol Biol Phys 81 2011 e631 e638
101. P Blake, AM Swart, J Orton the ASTEC/EN.5 Study Group Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis Lancet 373 2009 137 146
102. RA Nout, VTHB Smit, H Putter the PORTEC Study Group Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial Lancet 375 2010 816 823
103. B Sorbe, G Horvath, H Andersson, K Boman, C Lundgren, B Pettersson External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma - a prospective randomized study Int J Radiat Oncol Biol Phys 82 2012 1249 1255
104. A Kong, N Johnson, HC Kitchener, TA Lawrie Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis J Natl Cancer Inst 104 2012 1625 1634
105. M Kunneman, AH Pieterse, AM Stiggelbout et al. Treatment preferences and involvement in treatment decision making of patients with endometrial cancer and clinicians Br J Cancer 111 2014 674 679
106. N Susumu, S Sagae, Y Udagawa the Japanese Gynecologic Oncology Group Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study Gynecol Oncol 108 2008 226 233
107. R Maggi, A Lissoni, F Spina et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial Br J Cancer 95 2006 266 271
108. ME Randall, VL Filiaci, H Muss the Gynecologic Oncology Group study Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 24 2006 36 44
109. CP Morrow, BN Bundy, HD Homesley et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study Gynecol Oncol 36 1990 166 171
110. T Kuoppala, J Mäenpää, E Tomas et al. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs sequential chemo-radiotherapy Gynecol Oncol 110 2008 190 195
111. T Hogberg, M Signorelli, CF de Oliveira et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer - results from two randomised studies Eur J Cancer 46 2010 2422 2431
112. DS McMeekin, VL Filiaci, JT Thigpen, HH Gallion, GF Fleming, WH Rodgers the Gynecologic Oncology Group study The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study Gynecol Oncol 106 2007 16 22
113. AN Fader, RD Drake, DM O'Malley the Uterine Papillary Serous Carcinoma (UPSC) Consortium Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma Cancer 115 2009 2119 2127
114. DS McMeekin, VL Filiaci, C Aghajanian et al. A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): a Gynecologic Oncology Group trial Gynecol Oncol 134 2014 438 (abstr).
115. RR Barakat, NA Goldman, DA Patel, ES Venkatraman, JP Curtin Pelvic exenteration for recurrent endometrial cancer Gynecol Oncol 75 1999 99 102
116. LS Bradford, JA Rauh-Hain, J Schorge, MJ Birrer, DS Dizon Advances in the management of recurrent endometrial cancer Am J Clin Oncol 38 2015 206 212
117. LM Landrum, KN Moore, TK Myers et al. Stage IVb endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis Gynecol Oncol 112 2009 337 341
118. JN Barlin, I Puri, RE Bristow Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis Gynecol Oncol 118 2010 14 18
119. T Eto, T Saito, T Kasamatsu et al. Clinicopathological prognostic factors and the role of cytoreduction in surgical stage IVb endometrial cancer: a retrospective multi-institutional analysis of 248 patients in Japan Gynecol Oncol 127 2012 338 344
120. T Eto, T Saito, M Shimokawa et al. Status of treatment for the overall population of patients with stage IVb endometrial cancer, and evaluation of the role of preoperative chemotherapy: a retrospective multi-institutional study of 426 patients in Japan Gynecol Oncol 131 2013 574 580
121. E Despierre, P Moerman, I Vergote, F Amant Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma? Int J Gynecol Cancer 16 suppl 1 2006 273 277
122. CW Whitney, VL Brunetto, RJ Zaino the Gynecologic Oncology Group study Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 92 2004 4 9
123. RF Asbury, VL Brunetto, RB Lee, G Reid, TF Rocereto the Gynecologic Oncology Group Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study Am J Clin Oncol 25 2002 557 560
124. K Lindemann, S Malander, RD Christensen et al. Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO) BMC Cancer 5 2014 14 68
125. N Colombo, DS McMeekin, PE Schwartz et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial Br J Cancer 108 2013 1021 1026
126. D Tsoref, S Welch, S Lau et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer Gynecol Oncol 135 2014 184 189
127. A Oza, S Pignata, A Poveda et al. Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma J Clin Oncol 2015 10.1200/JCO.2014.58.8871 published online June 15.
128. BM Slomovitz, KH Lu, T Johnston et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer 116 2010 5415 5419
129. AM Oza, L Elit, MS Tsao et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group J Clin Oncol 29 2011 3278 3285
130. BM Slomovitz, Y Jiang, MS Yates et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma J Clin Oncol 2015 10.1200/JCO.2014.58.3401.org published online Jan 26.
131. U Matulonis, I Vergote, F Backes et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma Gynecol Oncol 136 2015 246 253
132. V Makker, FO Recio, L Ma et al. Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: final study results J Clin Oncol 32 suppl 2014 5513 (abstr).
133. RL Coleman, MW Sill, PH Thaker et al. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study Gynecol Oncol 138 2015 30 35
134. E Teplinsky, F Muggia Targeting HER2 in ovarian and uterine cancers: challenges and future directions Gynecol Oncol 135 2014 364 370
135. T Febbraro, E Lengyel, IL Romero Old drug, new trick: repurposing metformin for gynecologic cancers? Gynecol Oncol 135 2014 614 621
136. KJ Dedes, D Wetterskog, A Ashworth, SB Kaye, JS Reis-Filho Emerging therapeutic targets in endometrial cancer Nat Rev Clin Oncol 8 2011 261 271
137. V Castonguay, S Lheureux, S Welch et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia Gynecol Oncol 134 2014 274 280
138. MA Powell, MW Sill, PJ Goodfellow et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study Gynecol Oncol 135 2014 38 43
139. ITM Vergote, MA Powell et al. A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes J Clin Oncol 31 suppl 2013 5520 (abstr).
140. EA Alvarez, WE Brady, JL Walker et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 129 2013 22 27
141. G Emons, G Gorchev, J Sehouli et al. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5) Gynecol Oncol 133 2014 427 432
142. Swisher EBJ, Kaufmann S, et al. ARIEL2. A phase 2 study to prospectively identify ovarian cancer patients likely to respond to rucaparib. 26th EORTC-NCI-AACR symposium on molecular therapeutics; Barcelona, Spain; Nov 18-21, 2014. Abstract 215.
143. MD Forster, KJ Dedes, S Sandhu et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer Nat Rev Clin Oncol 8 2011 302 306
144. Z Gatalica, C Snyder, T Maney et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type Cancer Epidemiol Biomarkers Prev 23 2014 2965 2970
145. BE Howitt, SA Shukla, LM Sholl et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1 JAMA Oncol 2015 10.1001/jamaoncol.2015.2151 published online July 9.
146. GL Moir-Meyer, JF Pearson, F Lose the Australian National Endometrial Cancer Study Group the Hunter Community Study the Studies of Epidemiology and Risk Factors in Cancer Heredity Rare germline copy number deletions of likely functional importance are implicated in endometrial cancer predisposition Hum Genet 134 2015 269 278
147. JM Lancaster, CB Powell, ND Kauff the Society of Gynecologic Oncologists Education Committee Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions Gynecol Oncol 107 2007 159 162
148. DD Buchanan, YY Tan, MD Walsh et al. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimises triage for population-level germline mismatch repair gene mutation testing J Clin Oncol 32 2014 90 100
149. V Bonadona, B Bonaïti, S Olschwang the French Cancer Genetics Network Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome JAMA 305 2011 2304 2310
150. KM Schmeler, HT Lynch, LM Chen et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome N Engl J Med 354 2006 261 269
151. LM Chen, KY Yang, SE Little, MK Cheung, AB Caughey Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families Obstet Gynecol 110 2007 18 25
152. L Renkonen-Sinisalo, R Bützow, A Leminen, P Lehtovirta, JP Mecklin, HJ Järvinen Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome Int J Cancer 120 2007 821 824
153. F Lécuru, MA Le Frère Belda, AS Bats et al. Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study Int J Gynecol Cancer 18 2008 1326 1331
154. E Crosbie, J Morrison The emerging epidemic of endometrial cancer: Time to take action Cochrane Database Syst Rev 12 2014 ED000095
155. H Arem, Y Park, C Pelser et al. Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients J Natl Cancer Inst 105 2013 342 349
156. C Liao, D Zhang, C Mungo, DA Tompkins, AM Zeidan Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies Gynecol Oncol 135 2014 163 171
157. Committee on Gynecologic Practice Committee opinion no. 619: Gynecologic surgery in the obese woman Obstet Gynecol 125 2015 274 278
158. JR Robbins, OH Gayar, M Zaki, M Mahan, T Buekers, MA Elshaikh Impact of age-adjusted Charlson comorbidity score on outcomes for patients with early-stage endometrial cancer Gynecol Oncol 131 2013 593 597